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Pharmaceutical Industry
Dragan Kesiˇ c
The main purpose of the paper is to research and evaluate the strategic
development trends in the world pharmaceutical industry in the pe-
riod 1996–2006.W ea i mt oﬁ n dt h a tm e r g e r sa n da c q u i s i t i o n sp r e v a i l
as a vital strategic developmentoption in the world pharmaceutical in-
dustry. The research examines the exploratory hypothesis that the in-
tensive globalization process, increased competitiveness and changed
structure of competitors, strongly inﬂuence the consolidation develop-
ment trends in the world pharmaceutical industry which result in an
increased number of mergers and acquisitions. The intensive consoli-
dation of the world pharmaceutical industry is a market driven process
and conditioned by several strategic issues, such as lack of brand new
products, increased competitiveness, fast globalization process, inten-
sive global marketing and sales activities, changed structure of com-
petitors, ﬁght for global market shares and customers’ loyalty. There is
clear evidence that the world pharmaceutical industry and market are
both becoming more oligopolistic and monopolistic.
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Introduction
We may deﬁne the major characteristics of the world pharmaceutical in-
dustry as follows:
￿ increased globalization,
￿ changing structure of competition and increased competitiveness,
￿ lackofbrandnewproducts,despiteincreasedinvestmentsintor&d
(Research & Development) activities,
￿ increasedimportanceofregulatory issues(registrations, intellectual
property rights, litigations),
￿ fast consolidation and concentration of the world pharmaceutical
industry,
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￿ development of new therapeutic ﬁelds and technologies (biotech-
nology, pharmacogenomics),
￿ ageing of the world population and opening up of new,not yet cov-
ered therapeutic ﬁelds,
￿ quick development of world generic markets.
Theworldpharmaceuticalmarkethasundergonefast,unprecedented,
tremendous and complex changes in the last several years. The phar-
maceutical industry is today still one of the most inventive, innovative
andthe mostlucrativeof the worldso-called‘high-tech’ industries, how-
ever we may speak at the same time of the period of great and profound
changes in this industry sector. We may say that the pharmaceutical in-
dustry has been adapting itself more to the market trends and market
demands.Thepharmaceuticalindustrytodayprobablyunitesthebiggest
ofallthe humankindpotentials.Developmentofabrandnewdrug (nas
– New Active Substance) is today estimated to need investment over 1.2
billion usd and takes over 12 years to bring it as a ﬁnished, legally reg-
istered and approved product to the market place (World Review 2007).
This is at the same time a very complex, comprehensive and highly risky
job with no ﬁnal guarantee that a new product might succeed on the
market and bring revenues back. If a pharmaceutical company wants
to achieve market success, with a brand new product, it needs to invest
heavily into marketing and sales activities. As we may observe, the ba-
sic research and development activities (r&d), together with marketing
and sales activities, are two of the most important activities of the world
pharmaceutical industry. Here the biggest investments of the pharma-
ceutical industry are being poured in. Having analysed these ﬁgures, we
have found that the biggest, inventive pharmaceutical companies invest
on average around 16% of their sales into r&d and even more, around
25%orevenmore,intomarketingandsalesactivities (Kesiˇ c2006).How-
ever, these ratios, especially those for r&d investments, are even higher
withspecialists, likebiotechnology andpharmacogenomicpharmaceuti-
cal companies, and much lower with generic pharmaceutical companies
(Kesiˇ c 2006). As mentioned, the world pharmaceutical industry is struc-
turallynotunique,aspharmaceuticalcompaniesdiﬀeraccordingtotheir
basic performances, vision and strategic development. In our research
we found that there are three diﬀerent groups of world pharmaceutical
companies:
￿ pharmaceutical companies which work on basic research, devel-
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table 1 World pharmaceutical market from 2004–2008






notes Adapted from World Review 2009.
opment and marketing and sales of brand new, inventive, original
pharmaceutical products (so-called originators),
￿ pharmaceutical companies which work on development and sales
of generic products (so-called generic producers),
￿ pharmaceutical companies which work on basic research and de-
velopment of biotechnology and pharmacogenomic products and
technologies of new delivery systems (so-called specialists).
Theworldpharmaceuticalmarkethasbeengrowingsteadilyinthelast
years. In the year 2006, the world pharmaceutical market achieved total
sales of 643 billion usd and a growth rate of 7% (World Review 2007).
The fastest growing world markets and regions are the markets of China,
CentralEast European region (Russia,Poland andRomania)and certain
markets of Latin America (Brazil, Mexico and Chile).
We may argue that products are the main growth drivers forthe world
pharmaceutical companies. Pharmaceutical companies strongly com-
pete on products’ characteristics and tend to invest heavily into market-
ingactivitiesintheendeavourtogainprescribers’/patients’ loyaltyandto
compete also directly with other pharmaceutical companies. According
to this, it is no surprise that the biggest world multinational pharmaceu-
tical companies invest over 25% of their sales into marketing and sales
activities in the endeavour to gain considerable global market shares.
We may deﬁne a generic product as bioequivalent product with the
same active ingredient as an inventive, original one and it is subject to
standard registration procedure as is the original one, too. Nevertheless,
it is only legally allowed for a generic product to be launched upon ﬁnal
expiration of all pending intellectual property rights (patents expiry).
According to this aspect, and taking into account the fact that generic
producers do not need to invest huge sums of money into basic r&d
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activities, they compete only on the lower prices of their products. De-
velopment of a particular world generic market is in strong connection
with the existing legislation, which may favour or not the development
and growth of the same.
The world pharmaceutical industry has undergone deep changes in
the last decade. Most notably, the strong process of consolidation and
concentration has been going on, practically in all three deﬁned phar-
maceutical sectors; numerous mergers and acquisitions have occurred,
resulting in the forming of complete new companies. We may mention
just the most signiﬁcant ones to illustrate the current situation for a bet-
ter understanding (Kesiˇ c 2003):
￿ in the group of inventive companies the several acquistions of the
usa Pﬁzer (Warner Lambert, Pharmacia), the merger of GlaxoW-
ellcome and SmithKlineBeecham to create GlaxoSmithKline, the
merger of Astra and Zeneca to create AstraZeneca, the merger of
Ciba Geigy and Sandoz to form Novartis,
￿ in the group of generic companies the leading Israeli company Teva
has performed over 15 big acquisitions in the last decade, having
acquired the usa generic company Ivax as the last one; as well
Swiss Sandoz, which is a generic group, owned by Novartis, has
acquired likewise several generic companies worldwide, including
Lek in Slovenia, Hexal from Germany and Eon Labs. from the usa
as the last ones; in the year 2006 the usa Barr Pharmaceuticals ac-
quired the Croatian pharma company Pliva and recently the usa
major generic player Mylan acquired the German generic entity
Merck Generics,
￿ in the group of specialists, the usa biotech company Amgen has
been greatlyacquisitive,predominantlyin the usa,ha vingacquir ed
four specialists in the same group segment.
Theoretical Background
We may say that globalization is almosta synonymfor the modern econ-
omy. Globalization could not be possible without fast and profound
technological achievements and changes. Nowadays the global compe-
tition is mostly based on the knowledge and technology and ability to
serve the customers properly, swiftly and repeatedly. Globalization has
become almost a synonym for an economic liberalisation and foremost
openingoftheworldeconomies.However,alongsidethemarket,compe-
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tition has changed as well. The previous meaning of internationalization
has been replaced by a globalization domain and the previous meaning
of the world economy has been replaced by a global economy. oecd de-
ﬁnes globalization as ‘Spreading and deepening of companies’ perfor-
mance with the target to produce and sell goods or services on mul-
tiple markets’ (oecd 1993). The later deﬁnition of globalization from
oecd (1994) says that ‘More precisely we may deﬁne globalization as
a developing pattern of international business cooperation, which in-
cludes investments, trade and contractory ways of cooperation, and tar-
gets the development of products, production, procurement and mar-
keting. Such kind of international performance enables the companies
to conquer new markets, use their technological and organisational ad-
vantages and to lower the costs and risks.’ Globalization is strongly re-
latedwiththeincreasedmobilityandcompetition. Weunderlinethatthe
main drivers of globalization are transnational or multinational compa-
nies. We may argue that the following characteristics are signiﬁcant for
theirperformance;especiallytakingintoconsiderationtheperformances
of the multinational companies in the pharmaceutical industry, we aim
to research in our paper the following eﬀects:
￿ multinational pharmaceutical companies have had a strong market
position on the most important and strategic world markets with
holding of considerable market shares,
￿ they globally integrate and connect their business performance, so
national identity is no longer important,
￿ they perform a ﬂexible purchasing management strategy,
￿ have had a global network structure of production,
￿ have had a global network organisation of research and develop-
ment activities,
￿ have built a global marketing organization structure which sup-
ports a dedicated market orientation and a strategic priority focus
on customers.
We may even emphasize that globalization is in its core meaning a
complex,marketconditionedprocess, which isrelated toanddrivenbya
whole palette ofelements ofthe marketway of thinkingandperforming,
sudden, fast changes and ever-changing ways of doing business, along-
side an increasing competition and competitiveness, in striving to op-
timally identify changing needs of the world customers and to be able
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to satisfy their longterm needs. In this way we underline that globaliza-
tion is a market driven process. Thus, in the process of globalization it
is essential to be fast, to be strongly market oriented, to have loyal cus-
t o m e r s ,t ob ei n n o v a t i v e ,t oh a v ep r o p e rk n o w l e d g e ,t ob ea b l et ol e a r n
fast, to have proper information and to take quick decisions. Drucker
(1992) mentioned ﬁve of the most important elements of development
which would inﬂuence greatly the strategies, structure and performance
of future companies:
￿ economic relations would be performed in the direction among
trade blocs instead of countries,
￿ businessperformancewouldbemoreandmoreamatterofstrategic
alliancing, which would be integrated into the world eceonomy,
￿ restructuring of business would be intensifying and more globalis-
ing; it would be important to have information and knowledge,
￿ strategic management of companies would be decisive for a com-
petitive success,
￿ intensive market orientation of companies would be a core advan-
tage for achieving competitive advantage over competitors.
Svetliˇ ciˇ c( 1996) deﬁned globalization as:
￿ a multidimensional process, which includes economic, political, le-
gal and cultural contents, which together create a new quality,
￿ globalization means the global internationalisationor at least inter-
nationalisationofactivities suchastrade,foreigndirect investments
(fdi), contractual ways of international economic cooperation in
the most important markets,
￿ globalization supports common alliancing, which needs the global
coordination and integration of activities in a brand new manner,
￿ globalization means production, on the basis of the same products,
for domestic consumption and foreign markets as well; the prod-
ucts are able to satisfy local needs and habits,
￿ globalization means a high share of components from foreign sup-
pliers in the products for domestic consumption and for export as
well.
Globalization is a non-return process, and without intensive interna-
tionalisation performance of companies in the modern world, it would
notprogress.BartlettandGhosal(1989)underlinedthat‘Successful com-
panies oftoday andtomorroware those oneswho are ableto satisfy local
Managing Global TransitionsStrategic Development Trends in the World Pharmaceutical Industry 213
needs, increase global eﬀectiveness and strive for a constant innovative-
ness and global learning at the same time.’
Research Questions –Exploratory Hypothesis
The main purpose of paper is to research and evaluate the strategic de-
velopment trends in the world pharmaceutical industry in the period
1996–2006. The pharmaceutical industry is chosen as it is quite com-
plex, highly inventive and regulated, competitive and has been changing
profoundly, concentrating and consolidating strongly in the last decade.
Besides that, there are a relatively small and limited number of research
papers on the pharmaceutical industry available worldwide as well. We
aim to ﬁnd out what are the core reasons for the huge and increasing
number of mergers and acquisitions in the world pharmaceutical indus-
try. According to our knowledge, there are no research papers with this
complex content yet available in the world literature.
There are three main research questions – exploratory hypotheses we
would like to study with regard to the research work we aim to perform:
h1 The globalization process, lack of new products and ﬁght for global
market shares supports the concentration and consolidation in the
worldpharmaceuticalindustry whichisbecoming more oligopolistic.
h2 Concentration and consolidation is evident in all three sectors of the
world pharmaceutical industry.
h3 Increased competitiveness and the changed structure of competitors
further inﬂuence concentration and consolidation in the world phar-
maceutical industry.
Methodologyand Data
We aim to evaluate the strategic development trends of the world phar-
maceuticalindustryin theperiod 1996–2006,aswemaketheexploratory
hypothesis that the world pharmaceutical industry has been consolidat-
ing strongly in that period and we would like to ﬁnd out what are the
main reasons for such a developmenttrend. In our research work we en-
deavour to use the analytical, comparative, descriptive methods and a
method of strategic analysis, strategic diagnosis and strategic prognosis
to determine the development trends in the world pharmaceutical in-
dustry in the analysed period. We plan to use in our research work a
variety of all literature, diﬀerent sources and publicly available data and
information,predominantlyonthebusinessstrategiesandperformances
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of world pharmaceutical companies, world pharmaceutical markets and
developmenttrends within the pharmaceutical industry. Nevertheless, it
should be strongly emphasized that there is relatively scarce and limited
literature anddata atour disposal onthe world pharmaceuticalindustry,
especiallytakingintoaccounttheresearchobjectives,asonlyverylimited
worldliterature,sources, informationanddataontheworldpharmaceu-
tical industry are indeed publicly available.
DataAnalysis and Findings
In our research we found that competitiveness in the world pharmaceu-
tical industry has been increasing tremendously in the analysed period.
Wefoundthatthepharmaceuticalindustryhasbeenintheintensivepro-
cesses of concentration and consolidation for a period of over 15 years.
We found, and thus may argue, that research & development and mar-
keting&sales activities are two of the most important and strategic pri-
orities of the pharmaceutical companiesand into which the greatest part
of funds are being invested as well. According to our research work, we
may say that the main strategic reasons for the intensive consolidation
processes of the world pharmaceutical industry, which result in m&a
(Mergers and Acquistions) activities, are the following:
￿ fast globalization processes of the world economy,
￿ lack of brand new products to drive sales growth further,
￿ huge investments needed for r&d activities,
￿ global marketing and sales activities which need large investments
as well,
￿ increased competitiveness,
￿ changed structure of competitors,
￿ increasedimportanceofregulatory issues(registrations,intellectual
property rights, litigations).
Wehaveprecisely studied all availablepublished pharmaceutical com-
panies’ data on their merger and acquisition activities and reasons for
such a chosen strategy. According to our research study and ﬁndings,
there have been more than 10,000 various alliances formed in the world
pharmaceuticalindustry in the last decade(Datamonitor 2005).We have
found that consolidation processes have been carried out practically
in all three sectors (innovative – original pharmaceutical companies,
generic producers and specialists) of the world pharmaceutical industry.
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table 2 Overview of the major strategic mergers and acquisition in the world
pharmaceutical industry from 1995–2005
Year Strategic mergers and acquistions
1995 Glaxo – Wellcome/GlaxoWellcome(a)
1995 Pharmacia – Upjohn/Pharmacia&Upjohn (m)
1995 Hoechst – Marrion Merrell Dow/hmr(a)
1995 rpr –F i s o n s /rpr(a)
1995 Ranbaxy – Ohm Laboratories/Ranbaxy (a)
1995 basf – Boots/basf (a)
1997 Ciba – Sandoz/Novartis (m)
1997 Roche – Boehringer Mannheim/Roche (a)
1998 Pharmacia&Upjohn – Sugen/Pharmacia & Upjohn (a)
1998 Johnson& Johnson– Centocor /Johnson& Johnson(a)
1999 Astra – Zeneca/AstraZeneca (m)
1999 hmr – rpr/Aventis (m)
1999 Sanoﬁ – Synthelabo/Sanoﬁ-Synthelabo (m)
2000 Pharmacia&Upjohn – Monsanto (Searle)/Pharmacia (m)
2000 GlaxoWellcome – skb/GlaxoSmithKline(m)
2000 Pﬁzer – Warner Lambert/Pﬁzer (a)
2000 Abbott – basf Pharma – Knoll/Abbott (a)
2000 Teva – Lemmon, Biogal, ici, aps/Berk, Biocraft, Pharmachemie, Copley,
Novopharm (a)
2000 WatsonPharm. – Schein Pharm./WatsonPharmaceuticals (a)
2000 Ranbaxy – Bayer Basics/Ranbaxy (a)
2000 Elan – Dura Pharmaceuticals/Elan (N)
2000 Novartis/Novartis Generics – basf Pharma Generics – Knoll Generics;
Apothecon Inc./ Novartis/Novartis Generics (a)
2001 Novartis/Novartis Generics – Labinca, Lagap Pharmaceuticals/Novartis/Novartis
Generics (a)
2001 AlmirallProdesfarma – Prasfarma,Pharmafarm/AllmiralProdesfarma(a)
2001 Johnson&Johnson– Alza/Johnson&Johnson(a)
2001 bms – DuPont Pharmaceuticals/bms(a)
2001 Barr Laboratories – Duramed Pharmaceuticals/Barr Laboratories (a)
2001 Roche – Chugai Pharmaceuticals/ChugaiPharmaceuticals – Roche (a)
2002 Amgen – Immunex/Amgen (a)
2002 Chinoin/Sanoﬁ-Synthelabo– Pharmavit/Chinoin/Sanoﬁ-Synthelabo(a)
Continued on the next page
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table 2 Continued from the previous page
Year Strategic mergers and acquistions
2002 Schering ag – Collateral Therapeutics/Schering ag (a)
2002 Johnson& Johnson– Tibotec-Virco nv/Johnson& Johnson(a)
2002 Teva – Bayer Classics/Teva (a)
2002 Serono – Genset/Serono (a)
2002 Pﬁzer – Pharmacia/Pﬁzer(a)
2002 Novartis/Novartis Generics – Lek/Novartis/NovartisGenerics (Sandoz)– Lek (a)
2003 Johnson&Johnson– Scios/Johnson&Johnson(a)
2003 idec Pharmaceuticals – Biogen/Biogen idecInc. (a)
2003 Ranbaxy-rpg(Aventis)/Ranbaxy-rpg(a)
2003 Novartis – Mead Johnson/Novartis – Mead Johnson(a)
2003 Teva – sicor/Teva – sicor(a)
2003 Novartis/Sandoz – Amifarma/Novartis/Sandoz– Amifarma (a)
2003 Pﬁzer – Esperion Therapeutics/Pﬁzer – Esperion Therapeutics (a)
2004 Roche – Igen/Roche (a)
2004 Sanoﬁ-Synthelabo -Aventis/Sanoﬁ – Aventis (a)
2005 Pﬁzer – Vicuron Pharmaceuticals/Pﬁzer(a)
2005 Teva – ivax/Teva (a)
notes a–a c q u i s i t i o n ,m –m e r g e r .
The concentration process has practically created brand new pharma-
ceutical players; however some previously well-known pharmaceutical
ﬁrms have practically disappeared from the global market place. For ex-
ample, the world leading pharmaceutical company Pﬁzer has been cre-
atedfrom5biginternationalplayers,includingPﬁzeritself,WarnerLam-
bert, Upjohn, Searle and Pharmacia. GlaxoSmithKline has been formed
as well from 5 companies, including Smith, Kline, Beecham, Glaxo and
Wellcome. The leading generic global player, Teva from Israel, has ac-
quired so far over 15 generic companies worldwide to form today’s Teva.
We found in our research study that the transactions value in some
acquistions having been performed in the world pharmaceutical indus-
try exceeded several dozen of billions usd, which supports our research
outcomes that particular pharmaceutical companies still tend to invest
heavilyinendeavouringtogetstrategic controloversales,products, mar-
keting and sales activities, market shares and r&d capabilities of the ac-
quired pharmaceutical company.
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table 3 Overview of the largest merger & acquisition deals in the pharmaceutical
industry
Year Acquirer – target Transaction value in billion usd
2000 Pﬁzer – Warner Lambert 89
2000 GlaxoWellcome – skb 79
2009 Pﬁzer – Wyeth 68
2004 Sanoﬁ-Synthelabo – Aventis 66
2003 Pﬁzer – Pharmacia 61
2009 Roche – Genentech 48
1999 Zeneca – Astra 32
1999 hmr – rpr 28
1996 Sandoz – Ciba Geigy 28
2000 Pharmacia&Upjohn – Monsanto (Searle) 27
table 4 Overview of the latest pharmaceutical alliances in 2006–2007
Target – taken-over
company
Acquirer Creating of synergies
Schering ag,G e r m a n y B a y e r ,G e r m a n y r&d, markets, marketing&sales
Serono, Switzerland Merck kgaa,G e r m a n y r&d, markets, marketing&sales
Schwarz Pharma,Germany ucb,B e l g i u m r&d, products, markets, mar-
keting&sales
Altana Pharma, Germany Nycomed, Denmark r&d,m a r k e t s ,p r o d u c t s ,m a r -
keting&sales
Hospira, usa Mayne Pharma,
Australia
products, markets, sales
Pliva, Croatia Barr Pharmaceuticals,
usa
markets, products, r&d (bio-
generics), sales
Kos Pharmaceuticals, usa Abbott, usa r&d,p r o d u c t s
Organon BioSciences,
the Netherlands
Schering-Plough, usa r&d,m a r k e t s ,p r o d u c t s ,m a r -
keting&sales
MedImmune, usa AstraZeneca, ukr &d, markets, products (vac-
cines), marketing&sales
Merck Generics, Germany Mylan, usa markets, products, sales
Adnexus Therapeutics, usa bms, usa r&d,p r o d u c t s
We foundin our research that consolidation processes are still contin-
uing to even speed up as pharmaceutical companies try to follow their
competitors’ strategy of m&a (Mergers and Acquisitions) in endeavour-
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ing to maintain their global market position andlong-term competitive-
ness.Recentacquistionsofseveralpharmaceuticalcompaniesperformed
afterwards in the years 2006 and 2007 further conﬁrm our conclusions
of a fast consolidation and oligopolization of the world pharmaceutical
industry. This conﬁrms properly our third postulated exploratory hy-
pothesis.
In our research we found that the leading ten world pharmaceutical
companies currently command an over 43% market share of the global
pharmaceutical market. For a comparison reference, this ﬁgure was only
30% ten years ago (World Review 2007). This is a clear sign and proof
of how intensive market consolidation and concentration of the world
pharmaceutical industry has changed the world pharmaceutical market
in the analysed period. We also found that the number of new pharma-
ceutical products having been launched in the world market dropped
signiﬁcantly in the analysed period (from 34 in the year 1996 to only 21
in 2006 (World Review 2007)), thus supporting further consolidation
and concentrationof the world pharmaceutical industry, as products are
key drivers for sales growth of pharmaceutical companies. Thus they are
forced to search for new products by merger and acquisition strategies.
Very similarly, we found that the currently leading ten world generic
pharmaceutical companies achieve together an over 37%m a r k e ts h a r e
of the world generic market. For a comparison, this ﬁgure was only 18%
ten years ago (Datamonitor 2005). This is yet another proof of how in-
tensive consolidation of the world pharmaceutical industry has changed
both the world pharmaceuticalindustry and the market as well. Thus we
conﬁrmed our ﬁrst two postulated exploratory hypotheses.
We also found that the world pharmaceutical industry has become
more and more oligopolistic. We may support and refer this argumenta-
tionwiththeKnickerbrockertheoryofoligopolististicreaction(Knicker-
brocker 1973), which says that ‘Oligopolistic companies, as minimizators
of taking risks in avoidance of destroying eﬀects of competition follow
each other to new markets to protect their own interests. It is signiﬁcant
that the action of one player creates a reaction of the other competitors,
an action creates a reaction and so the story of oligopolisation is going
on.’ We may conclude that Knickerbrocker’s theory perfectly illustrates
and explains a consolidation process of the world pharmaceuticalindus-
try. By that we conﬁrmed our third postulated exploratory hypothesis.
It is evident that some stand-alone pharmaceutical companies are not
able to satisfy longterm and ever-changing market needs and customers’
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expectations, to invest heavily into r&d and marketing activities in the
endeavourtobringnewproductstoglobalmarketsandmaterialize them
properly. We can argue that this process enables pharmaceutical compa-
nies to generate new development circles and their long-term develop-
ment and growth. If a particular pharmaceutical company is not able to
perform the development circle on its own, it has to look for a suitable
partner with whom to form a kind of strategic partnership. Formation
of partnerships for the sake of maintaining long-term competitiveness
is today one of the most usable strategies in the world pharmaceutical
industry. We may argue that pharmaceutical companies make alliances
in endeavours to create common synergies and to better exploit their
commonassets, knowledge, product life cycles andmoreover to upgrade
their management strategies.
Pharmaceuticalcompaniestendtointernationalizeandglobalize their
business activities sooner thab in the past, due to market liberalization,
increased competitiveness and the need to react properly to strategic
consolidation and concentration activities of competitors.
According to that, Svetliˇ ciˇ c( 1996) stipulates that modern ways of in-
ternationalisation with an aid of network formation and strategic al-
liances enable internationalisation without a growth of companies. To-
day companies decide for internationalization and alliances in order to:
￿ be closer to customers,
￿ increase eﬀectiveness,
￿ gain better access to technologies and knowledge (know-how),
￿ protect them from competitors (strategic reasons).
We may say that, in a certain way, the concept of the strong market
oriented management clearly designates a company’s business philoso-
phy, respectively. We may agree with Corstjen’s (1991) estimation that
the ‘Sector of the pharmaceutical industry, despite being very speciﬁc in
all aspects, is an ideal case, how a practice and usage of the marketing
management concept directly relates to a very successful business per-
formance of this industrial sector.’
According to our research work, we found that the most important
andstrategic activities of creating common synergies for pharmaceutical
companies are the following:
￿ research and development (r&d), due to creating of brand new
products,
￿ products, due to driving sales growth and gain in market shares,
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￿ markets, due to creating geographic and market expansion,
￿ marketing and sales, due to enforcing marketing and sales activities
in order to compete on global markets and to drive further sales
growth.
These are the main reasons for strategic and intensive consolidation
trends in the world pharmaceutical industry. These facts clearly support
and conﬁrm our ﬁrst two proposed exploratory hypotheses.
We may say as well that, due to the complexity of the pharmaceuti-
cal industry, it is not unusual that the pharmaceuticalcompanies tend to
formpartnershipsandeventocompeteatthesametime. Theycancoop-
erate on some particular projects (for example r&d projects), however
theycompetestronglyforparticularmarketshares.Wehavefoundinour
research that this is the so-called ‘C and C phenomena’, as we may even
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call it ‘Co-opetition’ (cooperation and competition at the same time)
(Zineldin 2004).
Svetliˇ ciˇ c( 1996) properly underlined that the ‘Forming of alliances has
become attractive for companies due to:
￿ rising costs of innovation and entrance to new markets,
￿ reinforcing of cost reduction competition,
￿ pressure towards the enlarged gaining of synergistic technologies
and economies of scale and synergy with the help of alliances and
acquistions,
￿ the endeavourtoprotectexisting marketshares andtoconquernew
ones,
￿ the rising need to shrink time needed from an innovation till entry
onto the market with a product.’
According to our research work,we may argue that a dedicated strate-
gicmanagementwith sstrongmarketorientationisbynodoubt,besides
the r&d function, the most important function of the innovative com-
pany’s business performance in the pharmaceutical industry. Changes of
today’s, even of tomorrows’ world, are so fast and profound that it is
quite diﬃcult for the companies to follow them entirely. Nevertheless,
this is especially signiﬁcantfor the world pharmaceuticalindustry. How-
ever, changes do indeed represent new challenges and create new busi-
ness opportunities. Thus, it is important to react and act quickly, and to
be proactive. The urgency of fast adaptation is not just the strategy for
smaller companies and countries, but it is also a valid strategy of victori-
ous success for the bigger ﬁrms.
We may forecast that, taking into account the mentioned factors, fur-
ther consolidation and concentration of the world pharmaceutical in-
dustry is quite realistically expected. We may foresee the formation of
even bigger pharmaceutical concerns in all three sectors of the pharma-
ceutical industry. In addition, a further lack of brand new products is
expected with highly increased competitiveness and a furious ﬁght for
market shares and global customers’ loyalty.
Discussion and Conclusion
In our research work we found that the world pharmaceutical indus-
try has been changing profoundly over the last couple of years and that
an intensive globalization process deﬁnitively inﬂuences and reinforces a
consolidation of the world pharmaceutical industry. In order to explain
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this phenomenon properly, we have analysed in detail the trends in the
world pharmaceuticalindustry andkey reasons forsuch movements.We
provide empirical evidence that the intensive processes of concentration
and consolidation have been continuing in all three sectors of the world
pharmaceutical industry. Our research work shows that mergers and ac-
quisitions prevail more and more as a viable strategic orientation for
numerous world pharmaceutical companies. Further on, we may argue
that increased competitiveness and the amended structure of competi-
tors, which is conditioned by a merger and acquistion process, impact
the strategic orientation of particular world pharmaceutical companies.
By creating new alliances, they tend to create strategic synergies in the
endeavor to be even more successful, competitive and able to continue
with further development circles.
We may conclude that all four research questions/exploratory hy-
potheses put forward at the beginning of our research are entirely con-
ﬁrmed. We found that the intensive globalization process inﬂuences
the concentration and consolidation in world pharmaceutical industry,
which is becoming more oligopolistic and tending to be even more mo-
nopolistic in the future. Besides that, the lack of new products, ﬁght for
global market shares, increased competitiveness and changed structure
of competitors further supports the concentration and consolidation in
the researched industrial sector, and moreover, concentration and con-
solidation is evidentin all three deﬁned sectors of the world pharmaceu-
ticalindustry.By that wehaveconﬁrmedallthree postulated exploratory
hypotheses.
Thus we may forecast that intensive consolidation processes in the
worldpharmaceuticalindustry aretocontinuetoformevenbiggerphar-
maceutical ﬁrms and to speed up an oligopolization and even higher de-
gree of monopolization of the global pharmaceutical industry further
on. Based on our research ﬁndings, we may even forecast that in the fu-
ture there will be onlythree major groups of world pharmaceuticalcom-
panies: huge-mega inventive pharmaceutical companies, transnational
generic companies and focused specialists (biotechnology, pharmacoge-
nomics).Wemay pointoutthat the fastconsolidation ofthe worldphar-
maceutical industry is a market driven process and conditioned by typ-
ical strategic management issues, such as a lack of new products, inten-
sive and increasing competitiveness, fast globalization process, increased
global marketing and sales activities, a fast changing structure of global
competitors, and a furious ﬁght for the global market shares and cus-
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tomers’ loyalty. We may emphasize that a focused, straight-on strategic
management is going to play an even more important and especially a
decisive role in the future globalization and concentration processes of
the world pharmaceutical industry. We may further conclude that fu-
ture strategic development of the world pharmaceutical industry will be
predominantly dependent on the strategic management issues that the
pharmaceuticalcompanieswillbecapableofunderstanding„developing
and implementing properly in their operational and strategic business
performances. We may argue that strong market oriented management
practices are urgently needed for successful business performance today,
not to mention tomorrow and months and years to come, in this highly
globalized, transparent, complex, demanding, uncertain and competi-
tive world.
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